Nyxoah SA NYXH

NYXH Company Overview

Nyxoah SA is a Belgian medical technology company focused on developing and commercializing neuromodulation therapies for obstructive sleep apnea (OSA). The company operates within the medical devices and sleep health industries, with its primary product platform centered on hypoglossal nerve stimulation technologies intended to treat patients who are unable to tolerate continuous positive airway pressure (CPAP) therapy. Nyxoah’s core commercial and clinical efforts are concentrated on its proprietary Genio system, a battery-free, bilateral neurostimulation device designed to improve airway patency during sleep.

The company was founded in 2009 and is headquartered in Mont-Saint-Guibert, Belgium. Nyxoah evolved from an early-stage neurostimulation developer into a publicly traded medtech company listed on both Euronext Brussels and Nasdaq under the ticker NYXH. Its strategic positioning is tied to differentiated bilateral stimulation technology, minimally invasive implantation procedures, and a focus on addressing a large underserved patient population within the global OSA market. The company has pursued regulatory approvals and clinical expansion in both European and U.S. markets.